EP1242634A2 - Identification of virus-binding polypeptides and nucleotide sequences - Google Patents
Identification of virus-binding polypeptides and nucleotide sequencesInfo
- Publication number
- EP1242634A2 EP1242634A2 EP00952633A EP00952633A EP1242634A2 EP 1242634 A2 EP1242634 A2 EP 1242634A2 EP 00952633 A EP00952633 A EP 00952633A EP 00952633 A EP00952633 A EP 00952633A EP 1242634 A2 EP1242634 A2 EP 1242634A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- virus
- seq
- group
- membrane
- plant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 128
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 69
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 69
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 66
- 230000027455 binding Effects 0.000 title claims abstract description 64
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 59
- 241000016010 Tomato spotted wilt orthotospovirus Species 0.000 claims abstract description 55
- 239000002299 complementary DNA Substances 0.000 claims abstract description 46
- 239000013598 vector Substances 0.000 claims abstract description 42
- 241000927584 Frankliniella occidentalis Species 0.000 claims abstract description 23
- 230000014509 gene expression Effects 0.000 claims abstract description 21
- 241001465754 Metazoa Species 0.000 claims abstract description 16
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 241000196324 Embryophyta Species 0.000 claims description 39
- 241001414989 Thysanoptera Species 0.000 claims description 36
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 239000012528 membrane Substances 0.000 claims description 30
- 241000712894 Orthotospovirus Species 0.000 claims description 24
- 230000003612 virological effect Effects 0.000 claims description 24
- 239000002245 particle Substances 0.000 claims description 17
- 230000004927 fusion Effects 0.000 claims description 16
- 241000238631 Hexapoda Species 0.000 claims description 14
- 230000009261 transgenic effect Effects 0.000 claims description 13
- 241000712893 Impatiens necrotic spot virus Species 0.000 claims description 8
- 239000000020 Nitrocellulose Substances 0.000 claims description 7
- 229920001220 nitrocellulos Polymers 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 108020004414 DNA Proteins 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 4
- 239000004677 Nylon Substances 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims 1
- 108070000030 Viral receptors Proteins 0.000 abstract description 6
- 102000005962 receptors Human genes 0.000 description 34
- 108020003175 receptors Proteins 0.000 description 34
- 238000012216 screening Methods 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 18
- 102000003886 Glycoproteins Human genes 0.000 description 14
- 108090000288 Glycoproteins Proteins 0.000 description 14
- 238000010367 cloning Methods 0.000 description 14
- 238000003556 assay Methods 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 102000018265 Virus Receptors Human genes 0.000 description 10
- 108010066342 Virus Receptors Proteins 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 108010067390 Viral Proteins Proteins 0.000 description 9
- 230000007501 viral attachment Effects 0.000 description 9
- 241000150452 Orthohantavirus Species 0.000 description 8
- 241000150350 Peribunyaviridae Species 0.000 description 8
- 102000006495 integrins Human genes 0.000 description 8
- 108010044426 integrins Proteins 0.000 description 8
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000013459 approach Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 102000017776 integrin beta chain Human genes 0.000 description 6
- 108060004057 integrin beta chain Proteins 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 241000255925 Diptera Species 0.000 description 5
- 108091034057 RNA (poly(A)) Proteins 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000001418 larval effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 241000238421 Arthropoda Species 0.000 description 3
- 241000256113 Culicidae Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000713112 Orthobunyavirus Species 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 241000255129 Phlebotominae Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010805 cDNA synthesis kit Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011217 control strategy Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 239000003656 tris buffered saline Substances 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000256182 Anopheles gambiae Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 102000000541 Defensins Human genes 0.000 description 2
- 108010002069 Defensins Proteins 0.000 description 2
- 241000255601 Drosophila melanogaster Species 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- 241000256179 Ochlerotatus triseriatus Species 0.000 description 2
- 241000150218 Orthonairovirus Species 0.000 description 2
- 241000713137 Phlebovirus Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- GIXWDMTZECRIJT-UHFFFAOYSA-K aurintricarboxylate Chemical compound C1=C(C([O-])=O)C(O)=CC=C1C(C=1C=C(C(O)=CC=1)C([O-])=O)=C1C=C(C([O-])=O)C(=O)C=C1 GIXWDMTZECRIJT-UHFFFAOYSA-K 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229950000964 pepstatin Drugs 0.000 description 2
- 108010091212 pepstatin Proteins 0.000 description 2
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 230000008659 phytopathology Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- NGYHUCPPLJOZIX-XLPZGREQSA-N 5-methyl-dCTP Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NGYHUCPPLJOZIX-XLPZGREQSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 241000256173 Aedes albopictus Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 102400000310 Alpha-dystroglycan Human genes 0.000 description 1
- 241000256186 Anopheles <genus> Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 101710185173 Arylphorin Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000218993 Begonia Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101000779253 Bos taurus AP-3 complex subunit delta-1 Proteins 0.000 description 1
- 241000257163 Calliphora vicina Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 101710196022 Cuticle protein Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 244000115658 Dahlia pinnata Species 0.000 description 1
- 235000012040 Dahlia pinnata Nutrition 0.000 description 1
- 240000008853 Datura stramonium Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101100228149 Drosophila melanogaster Trl gene Proteins 0.000 description 1
- 108010071885 Dystroglycans Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 108010074122 Ferredoxins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 241001123946 Gaga Species 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001495448 Impatiens <genus> Species 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- 102000018170 Lymphotoxin beta Receptor Human genes 0.000 description 1
- 108010091221 Lymphotoxin beta Receptor Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001599018 Melanogaster Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000711466 Murine hepatitis virus Species 0.000 description 1
- 108091008604 NGF receptors Proteins 0.000 description 1
- 241001274216 Naso Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108700005081 Overlapping Genes Proteins 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 240000003889 Piper guineense Species 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 239000012721 SDS lysis buffer Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000853 biopesticidal effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 244000013123 dwarf bean Species 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000087 hemolymph Anatomy 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229930190166 impatien Natural products 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 101150056134 lacL gene Proteins 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000003449 plasmodesmata Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- -1 re Species 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000012865 response to insecticide Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000006394 virus-host interaction Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
Definitions
- viruses In animals, viruses generally enter host cells by the stepwise process of virus attachment, fusion and penetration. The attachment to the putative viral receptor, or virus-binding polypeptide, is the first event in this process. In the past and recent years, a diversity of cellular receptors have been identified for numerous animal viruses in the surface of their host cells.
- receptors for the human immunodefficiency-1 retrovirus include, for example, the receptors for the human immunodefficiency-1 retrovirus (Dalgleish et al, "The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus," Nature, 312:763-767 (1984)); the hepatitis A herpesvirus (Kaplan et al., "Identification of a surfce glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus," EMBO J.. 15:4284-96 (1996)); the rabies rhabdovirus (Hanham et al., "Evidence from the anti-idiotypic network that the acetylcholine receptor is a rabies virus receptor," _ Virol..
- Plant viruses are usually introduced into their plant host cells via the feeding of invertebrate vectors or via mechanical action using a process that involves the partial destruction of the plant's cell wall and perforation of its cellular membrane. Once introduced into the cell, the virus is then able to move from cell-to-cell using the filamentous structures between the cells, known as plasmodesmata.
- TSWV tomato spotted wilt virus
- Bunyaviridae the type member of the Tospovirus genus
- thrips which have an extremely high reproductive capacity, mainly the western flower thrips, Frankliniella occidentalis Pergande.
- the viral family Bunyaviridae has more than 300 members, making it one of the largest viral families.
- the Bunyaviridae family includes five genera: Bunyavirus, Hantavirus, Nairovirus, Phlebovirus and Tospovirus, encompassing some of the most dangerous of the emergent group of pathogens.
- Bunyaviridaes which are transmitted by rodents excreta aerosols
- all other members of the Bunyaviridae are transmitted by arthropods (mosquitos, sand flies, ticks, and thrips).
- Vertebrate hosts include humans, and other primates, mammals, birds, and ungulates.
- Tospovirus The genus Tospovirus is the only known viral genus in the Bunyaviridae family that is made up of plant-infecting viruses. They have an extremely wide host range and infect hundreds of plant species, ultimately causing diseases in many economically important cereal, vegetable, ornamental and fruit crops throughout the world. Examples of important plant hosts include potato, tomato, pepper, peanut, tobacco, pea, lettuce, cotton, onion, watermelon, chrysanthemum, impatiens, begonia, dahlia and others. Diseases caused by tospoviruses are also extremely difficult to control.
- virus vectors In addition to the tospoviruses, an enormous number of other plant viruses show a very specific relationship with virus vectors, mostly insects, wherein each virus or group of viruses is transmitted only by a specific vector.
- the specificity of each virus to its vector may be determined at the molecular level by recognition of a receptor, or other recognition or binding factors which stabilize or protect the virus in the vector organism.
- a number of different approaches have been used for identification and cloning of virus receptors, with the vast majority relying upon the capability of the virus or its viral attachment protein(s) to bind to host cells or to cell components.
- putative receptors have been partially purified by affinity chromatography, and then used for the development of anti-receptor antibodies and/or microsequencing, followed by use for immuno (Baldwin et al., "Molecular cloning and expression of receptor peptides that block human cytomegalovirus/cell fusion,” Biochem. Biophvs. Res. Commun.. 219:668-673 (1996)) or hyrbridization screening (Holmes et al., "Characterization and expression of the receptor glycoprotein for mouse hepatitis virus," New aspects of positive-strand RNA viruses. 253-256 (Brinton and Heinz (eds.) ASM Press, Washington D.C.
- virus receptor cloning strategies include the use of the yeast two-hybrid screening system (Matsumoto et al., "Hepatitis C virus core protein interacts with the cytoplasmic tail of lympho-toxin-beta receptor, " J.
- the present invention is summarized in that a novel method is disclosed for identifying virus-binding polypeptides, and the nucleotide sequences encoding them. Also disclosed are nucleotide sequences encoding tospovirus-binding polypeptides from the western flower thrips, Frankliniella occidentalis Pergande ("WFT"), identified using the method of the present invention.
- WFT Frankliniella occidentalis Pergande
- the present invention includes a method for identifying virus-binding polypeptides comprising the steps of constructing a cDNA library from total mRNA isolated from a virus vector; inducing expression of the cDNA library to obtain fusion polypeptides; transferring the fusion polypeptides onto a membrane; exposing the membrane to at least one viral particle; and detecting those expression products which bind to the viral particle.
- the cDNA library member associated with the bound fusion polypeptide may be sequenced to elucidate its nucleotide sequence.
- the present invention also includes nucleotide sequences encoding tospovirus- binding polypeptides identified in the western flower thrips, Frankliniella occidentalis Pergande, in accordance with the present invention.
- the present invention further includes a transgenic plant expressing a foreign protein encoded by a nucleotide sequence encoding a tospovirus-binding polypeptide identified in the western flower thrips, Frankliniella occidentalis Pergande, in accordance with the present invention.
- virus-binding polypeptides and their nucleotide sequences, can be identified without requiring a cellular virus infection or binding system.
- virus-binding polypeptides and their nucleotide sequences, can be identified without requiring partial or complete purification of the putative receptor.
- virus-binding polypeptides and their nucleotide sequences, can be identified without requiring identification, cloning and expression of a functional viral attachment protein.
- Fig. 1 is a graphical illustration of Tospovirus morphology and structure, genome organization, replication and expression strategies.
- Fig. 2 is an illustration of the method for cloning virus-binding polypeptides.
- Fig. 3 is a diagram illustrating the screening process.
- Fig. 4 is a table summarizing the results from a sequence analysis.
- Fig. 5 is a conceptual drawing representing the working hypothesis for receptor and co-receptor recognition by TSWV.
- Fig. 6 is a conceptual drawing representing the blocking of virus-receptor recognition by the expression of a virus-binding polypeptide in transgenic plants.
- Figure 7 is a conceptual drawing illustrating the mechanism of virus acquisition when vectors feed on infected plants.
- the method uses a cDNA expression library made from the total mRNA of a virus vector organism and a freshly purified preparation of a plant-infecting virus.
- the method is a variation of the far- Western technique in which protein-protein interactions can be detected similarly to the traditional antigen-antibody interactions detected in Western blotting.
- the process does not require cellular infection, nor another viral binding system, nor the identification of the viral protein responsible for binding in the virus.
- the purification of a putative viral receptor from the virus vector organism is also not required. Techniques such as the one described here are not normally used in studies of plant viruses, since plant viruses do not use receptors when infecting plant cells.
- TS WV-binding polypeptides from the western flower thrip, Frankliniella occidentalis Pergande. It will be understood that the principles of the invention apply as well to other types of plant-infecting viruses that use animal vectors, such as rhabdoviruses and other types of tospoviruses, such as the impatiens necrotic spot virus. Likewise, it will be understood that the principles of the present invention apply as well to other types of virus vectors, such as insects (e.g., mosquitos, sand flies, flies, and thrips), rodents, birds and other arthropods.
- insects e.g., mosquitos, sand flies, flies, and thrips
- rodents e.g., birds and other arthropods.
- virus-binding polypeptides begins by constructing a cDNA expression library from the total mRNA of a virus vector animal.
- a virus vector is defined to include those animals capable of carrying and transmitting viruses.
- virus vectors may include insects (e.g., mosquitos, sand flies, flies, and thrips), rodents, birds and other arthropods.
- virus vectors may include insects capable of carrying and transmitting bunyaviruses, nairoviruses, phleboviruses, rhabdoviruses and tospoviruses, such as the western flower thrips, Frankliniella occidentalis Pergande ("WFT"), which is known to carry and transmit the tomato spotted wilt virus (“TSWV”).
- WFT Frankliniella occidentalis Pergande
- TSWV tomato spotted wilt virus
- the cDNA library may be constructed using any one of the many molecular vector systems commonly known in the art.
- the lambda-based cDNA synthesis kit (Stratagene) may be used for the cDNA library construction. Lambda- based cDNA expression libraries show several advantages when compared to other methods.
- the cDNA library may be plated and cultured to begin the screening process.
- the screening process involves the use of a preparation of a plant-infecting virus to screen the fusion polypeptides produced by the members of the cDNA library to detect which fusion polypeptides, if any, exhibit virus-binding activity.
- the screening may be performed on any solid substrate suitable for protein detection, such as a nitrocellulose membrane, nylon membrane or pdf membrane.
- the detection system used may include any one of the many labeling systems employed in screening expression libraries. Such systems include, for example, monoclonal or polyclonal antibody systems which are selective to viral proteins.
- Fusion polypeptides are obtained by inducing expression of the plated cDNA library using an inducer which promotes transcription of the cDNA insert.
- the inducer may be applied to the cDNA library independently or in association with the membrane to facilitate the transfer of the fusion polypeptides to the membrane.
- the fusion polypeptides are transferred onto the membrane where they are exposed to a preparation of a plant-infecting virus.
- the preparation will generally include a purified solution of a native virus of interest, but may also include a solution of purified viral particles (native viral proteins).
- viral particles native viral proteins
- the most external viral protein is likely to be the actual binding ligand (viral glycoproteins in enveloped viruses, or capsid proteins in non-enveloped viruses), with antibodies against these proteins used for detection.
- purified viral particles instead of recombinant viral proteins, one can avoid potential problems with non-specific or abrogated binding caused by structural differences between the recombinant and the native viral protein, and additionally the viral protein cloning becomes an unnecessary process step.
- the initial advantage of using the present method is that several complex process steps are rendered unnecessary in the cloning process of the virus-binding polypeptide.
- the present invention does not require the induction of a cellular infection and/or a cellular binding system, or the identification, cloning and expression of a functional viral attachment protein, or the partial purification of a putative receptor.
- virus receptor candidates can be selected and cloned in a very short period of time, and used in subsequent experiments for determination of their biological relevance as a virus receptor.
- the present method does not eliminate the selection of polypeptides which are unrelated to the virus receptor, but bind to the virus with a similar or higher affinity, which can be as useful or even more useful than a virus' specific receptor in terms of the development of novel control strategies.
- the present method may also be used for deciphering other virus-host interactions, including the detection and identification of cytoplasmic host factors involved in virus replication, transcription, and/or pathogenesis when other viral proteins are used in the screening (e.g., the viral polymerase or the movement of the protein and their specific antibodies).
- virus-binding polypeptides may also lead to the discovery of control strategies via the development of inhibitors of virus entry, replication, transcription, movement and transmission. For example, direct expression in transgenic plants of DNA sequences encoding viral binding polypeptides is expected to result in virus tolerant and/or resistant plans.
- Virus-binding polypeptides may also be used for identification of virus attachment proteins (receptor-binding) which, in turn, can be fused to specific toxins and then expressed in transgenic plants to accomplish the specific control of insect vectors.
- the present method has been used to identify seven DNA sequence from the western flower thrips, Frankliniella occidentalis Pergande, which encode polypeptides that specifically bind to the tomato spotted wilt virus ("TSWV").
- the seven DNA sequences are partial sequences, i.e. not the entire sequence of native thirps genes, but encode sufficient portions of the binding domains of the thrips genes to bind TSWV virions.
- the sequences have been identified as pTRl 11 (SEQ ID NO:l), pTR211 (SEQ ID NO:2), pTR313 (SEQ ID NO:3), pTR411 (SEQ ID NO:4), pTR621 (SEQ ID NO:5), pTR711 (SEQ ID NO:6), and pTR821 (SEQ ID NO:7).
- TSWV has three single- stranded RNA segments encapsulated by a lipidic envelope of host origin.
- the virion contains four structural proteins including the L polymerase, the N nucleocapsid and two viral-encoded glycoproteins embedded in the envelope, Gl and G2, as all illustrated in Fig. 1.
- the viral glycoproteins may serve as viral attachment proteins for several enveloped viruses, an expected property because of the proteins external position in the virus particle.
- the Arginine-Glycine-Aspartate (RGD) motif has also been established as an integrin-receptor binding motif as it is typically found in glycoproteins of the extracellular matrix in both animal and plant cells, the RGD motif believed to be involved in adhesion of cells to the extracellular matrix.
- RGD Arginine-Glycine-Aspartate
- Gavrilovskaya et al. "3 integrins mediate the cellular entry of hantaviruses that cause respiratory failure," Proc. Natl. Acad. Sci. USA. 95:7074-7079 (1998).
- Gavrilovskaya et al. observed that hantavirus entry is RGD-independent, in agreement with the observation that Hantaviruses do not have an RGD sequence in their glycoprotein ORF.
- RGD motif is present in the 5' end of G2 in two tospoviruses, TSWV and Impatiens necrotic spot virus (INSV) and its role as a receptor- binding motif together with the role of ⁇ integrins as tospoviruses receptors are questions still not addressed.
- Gavrilovskaya demonstrated that ⁇ 3 integrins specifically mediate the entry of two different hantaviruses in their respective host cells and, thus, proposed ⁇ -integrins as the hantavirus receptor.
- TSWV binds to some transcriptional activator-like thrips polypeptides which, if confirmed in vivo, might represent TSWV co-receptors and a novel mechanism for virus entry.
- Figure 5 illustrates a model for the proposed interactions between these factors.
- Several potential novel virus control strategies based on the seven sequences presented here, as well on virus-binding sequences discovered in accordance with the method of the present invention, are plausible.
- One approach is based on the use of transgenic plants engineered to express the virus-binding polypeptides. These plants are expected to inhibit transmission by interfering with virus particles assembly (virus assembly is necessary for virus acquisition by thrips).
- the polypeptides will bind to the viral glycoproteins and block its interaction with virus RNAs.
- these plants are expected to inhibit transmission by interfering with virus-receptor recognition.
- virus-binding polypeptides will saturate receptor binding sites on the virus surface and prevent virus- receptor interaction in thrips vectors. This strategy is illustrated in Fig. 6.
- virus-binding polypeptides The inhibition of virus transmission caused by virus-binding polypeptides is expected to be effective against all or most tospoviruses because TSWV glycoproteins share about 80% identity with others in the genus. This provides a significant advantage over transgenic plants expressing the N gene, as plants transfected with the N gene are resistant only against the isolate from which the N gene was extracted. Additionally non-binding mutant viruses that will eventually arise would not be transmitted.
- Another envisioned approach is based on the use of vector specific biological pesticides. Virus-binding polypeptides exclusively found in vector species will be used for selection of specific ligands (TSWV glycoproteins). These specific ligands will be used in the construction of Bt toxin-fusion proteins that will be expressed in transgenic plants or sprayed on plants in the field. Such biopesticides will target tospovirus vectors while avoiding non-vector species.
- Another potential approach is based on the identification of chemical compounds and peptides that block TSWV-thrips interaction. Identified virus-binding polypeptides will be used for screening chemical compounds and small peptide libraries. Compounds and/or peptides that disrupt virus binding could be expressed in transgenic plants to inhibit viral binding directly or could be used to design virus-vector interaction blocking agents.
- VAP viral attachment protein
- the method described here can be also be adapted to the cloning of polypeptides that bind any viral proteins (L and/or N for example).
- Purified recombinant L and N proteins can be used in substitution to the whole virus particle in the overlay step and, instead of TSWV glycoproteins-bound polypeptides, polymerase- or capsid-bound polypeptides can be identified and cloned. Subsequently transgenic plants expressing these polypeptides can be obtained and are expected to be resistant to virus infection via interference with virus replication.
- Monoclonal anti-Gl/G2 antibodies (Bandla and Sherwood, "Production of monoclonal antibodies to the glycoproteins of tomato spotted wilt virus using antigens eluted from ChromaPhor stained gels," Phytopathology. 85:1205 (1995)) were coupled to Sepharose C1-4B beads (Sigma) by addition of cyanogen-bromide as described by Ausubel et al., Short Protocols in Molecular Biology. (John Wiley and Sons, Inc., New York, 1995), producing an antibody-Sepharose complex (Ab-Seph).
- TWWV was purified as described by Gonsalves and Trujillo, "Tomato spotted wilt virus in papaya and detection of the virus by ELISA," Plant Disease. 70:501-506 (1986), resuspended in 0.01 M NaSO 3 to 2 ⁇ g/ ⁇ l total protein and immediately incubated for 2 hours at 4°C with Ab-Seph (1 vol virus: lOvol Ab-Seph), resulting in the Ab-Seph-TSWV conjugate.
- Thrips and mosquito (Anopheles gambiae Giles) extracts were homogenized in SDS lysis buffer (0.5% SDS, 0.05 M Tris-HCl, pH 8.0, ImM DTT, 2mM leupeptin and pepstatin, 20mM iodoacetamide, 1 mM PMSF) at 4 ⁇ g/ ⁇ l total protein, boiled 5 minutes, added to 1 vol of RIP A correction buffer (1.25% NP-40, 1.25% Na- deoxycholate, 0.0125M NaPO 4 , pH 7.2, 2mM EDTA, 0.2 mM Na-vanadate, 50 mM Na- fluoride, 100 U/ml aprotinin, 2mM leupeptin and pepstatin, 20 mM iodoacetamide, ImM PMSF) and incubated 1 to 4 hours at 4°C.
- SDS lysis buffer 0.5% SDS, 0.05 M Tris-HCl, pH 8.0, ImM
- the insect extracts were then incubated with the Ab-Seph/TSWV conjugate (1:1 vol., empirically determined) for an additional 3 hours at 4°C. After this further incubation period, the mixture was centrifuged for 1 min at 10,000 x g in washing buffer (1% Triton X-100, 1% bovine hemoglobin, pH 8.0, 0.14 NaCl, 0.025% NaN 3 , 1% sodium dowxycholate, 0.1% SDS, 1 mM DTT), the surpematant was discarded and the pellet was resuspended in washing buffer.
- washing buffer 1% Triton X-100, 1% bovine hemoglobin, pH 8.0, 0.14 NaCl, 0.025% NaN 3 , 1% sodium dowxycholate, 0.1% SDS, 1 mM DTT
- nitrocellulose membranes were incubated with purified TSWV diluted in fresh blocking solution at 10 ⁇ g/ml of total protein overnight at 4°C.
- monoclonal anti-Gl antibody (1 : 100 in blocking solution) was used as primary antibody and anti-mouse IgG-horseradish peroxidase conjugate (Sigma) as the secondary antibody (1 :25,000).
- the ECLTM enhancer chemiluminescent reagent (Amersham) was used as substrate for detection followed by exposure of the blot to X- ray film (Kodak and LabScientific).
- thrips and mosquito whole extracts 120 ⁇ g of total protein were prepared in Laemmli buffer as described above. The thrips extracts were prepared suing larval stages since the previously detected 50 kDa candidate receptor protein is more abundant in larval than in adult extracts.
- Membranes were sequentially incubated in stripping buffer (2% SDS, 100 mM BME, 62 mM Tris, pH 6.8) 50 °C for 30 minutes to remove TSWV virions and antibodies, according to the manufacturers instructions (Amersham), and re-probed only with anti-Gl and secondary antibodies, without previous incubation with purified TSWV.
- stripping buffer 2% SDS, 100 mM BME, 62 mM Tris, pH 6.8
- Anti-Gl and secondary antibodies without previous incubation with purified TSWV.
- Four additional immunoprecipitation buffers containing nonionic detergents as Triton-XlOO and Nonidet-P40 were tested (data not shown), as well as buffering conditions.
- anti-idiotypic antibodies raised against anti-Gl /G2 monoclonal antibodies (Bandla et al., supra) were coupled to Sepharose beads as described before.
- the resulting anti-Ids-Seph complex was incubated with the insect extracts (1:1 vol) for 3 hours at 4°C, washed three times, resuspended in Laemmli buffer and boiled for 5 minutes.
- the Western blotting assay was conducted as described above but without any virus overlay, while anti-idiotypic antibodies raised against anti-viral glycoproteins antibodies obtained previously were used as the primary antibodies.
- Mosquitoes (Aedes triseriatus, A. albopictus and Anopheles gambiae) were used as negative controls.
- the antibodies were cross-absorbed (an anti-IdGl+anti-IdG2 mixture) by incubation with whole mouse serum (Sigma) at 4 °C for 3 hours, and collecting the supernatent after 30 minutes of centrifugation at 14,000 x g in a microcentrifuge.
- Chemiluminescence relative to background of the detected 50 kDA proteins was measured with Lumi-ImagerTM (Boehringer Mannheim) in Boehringer light units (BLU)(representing the chemiluminescent light released by the peroxidase-luminol reaction.)
- the far- Western assay detected a 50 kDa thrips factor (protein) in the thrips extracts as previously reported by Bandla et al., supra, possibly representing the TSWV receptor or a receptor component.
- a second factor at about 65 kDa was also detected, although less evident, possibly representing a second receptor or receptor component.
- Both thrips proteins were also detected in the Western blotting assay when anti-idiotypic antibodies (anti-Ids) were utilized as the primary antibody. Such anti-Ids are considered to mimic the original ligand structure and are frequently used for receptor recognition in several different systems (Gaulton & Greene, 1986).
- Poly(A) + RNA (mRNA) was purified by affinity chromatography using biotin-oligo(dT)-streptavidin beads (PolyATractTM, Promega, Madison, WI) in three rounds of purification.
- Northern hybridization analysis of total and mRNA samples was performed after formaldehyde- 1% agarose gel electrophoresis using an actin universal DNA probe (pActin-1 clone, provided by the S. Carroll's laboratory, Dept. Genetics, UW-Madison) labeled with [ ⁇ - 32 P]-dATP to monitor the synthesis reaction.
- Rnase H, DNA polymerase I, and dNTPs were then added to the first-strand synthesis reaciton product (a DNA/mRNA hybrid) to obtain the second- strand cDNA by 'nick translation'.
- 100 ⁇ g of total RNA and 5 ⁇ g of poly(A) + RNA were obtained from the 100 mg of F. occidentalis larval tissue.
- Ribosomal RNA bands were visualized on a 1% denaturing agarose gel by ethidium bromide staining. Analysis of the results showed the 18S rRNA a and b fragments at the 1.8 kb position, as expected.
- a Drosophila melanogaster actin probe hybridized to an 800 bp RNA species, as expected, before and after mRNA isolation.
- ⁇ -ZAP cDNA synthesis kit (Stratagene, San Diego, CA) was used according to the manufacturer's instructions with some modifications.
- Poly(A) + RNA was added to oligo(dT) linker-primer (5* GAGAGAGAGAGAGAGAACTAGTCTCGAGT TTTTTTTTTTTTTTTTT 3'), which contains an. ⁇ 7j ⁇ l site (underlined) for sense- oriented insertion in the UniZAP XR ⁇ vector, with respect to the lacL promoter, a GAGA sequence to protect the restriction site, and a 18-base poly(dT) sequence that binds to the 3' poly(A) region fo the mRNA templates, MMLV reverse transcriptase, 5- methyl dCTP (to protect the cDNA from subsequent digestion reaction), and dNTPs to obtains the first-strand cDNA using [ ⁇ "32 P]-dATP to monitor the reaction.
- RNA extracted with aurin tricarboxylate resulted in a wider range of cDNA when compared to RNA extracted with TRITM reagent.
- cDNA fragments that were size-fractionated (0.5-10kb) and used in the ligation reaction to the ⁇ -ZAP XP vector (Stratagene).
- Primary library titer was determined by plaque assay as 2 x 10 5 pfu and 6 x 10 9 pfu/ml after amplification.
- cDNA fragments ranging from 0.5 to 10 kb were recovered by silica-gel columns (QIAquickTM, Qiagen, St. Clarita, CA). After gel recovery, cDNA inserts were ligated in the Uni-ZAP XR ⁇ vector containing XhoX and EcoRX cohesive ends for directional cloning into the pBluescript plasmid sequence, under the control of the lacZ promoter (Stratagene), using T4 DNA ligase according to the manufacturer's instructions.
- the Gigapack II extract (Stratagene) was used for in vitro packaging of the recombinant phages (Kretz et al., " Gigapack ® III high efficiency lambda packaging extract with single-tube convenience," Strategies Mol. Biol., 7:44-45 (1991)), resulting in infectious recombinant ⁇ phase particles.
- the primary library was produced by infecting E. coli XL 1 -blue (Bullock et al., "XL 1 -blue: A high efficient plasmid transforming recA Escherichia coli strain with ⁇ - galactosidase selection," BioTechniques. 5:376-379 (1987)) with the above recombinant phages. Titer was determined by a plaque assay to reveal a titer of 2 x 10 5 pfu.
- the TSWV Hawaiian strain was maintained by thrips inoculation in Datura stramonium (provided by D. Ullman's laboratory, Dept. Entomology, UC-Davis). Virus purification was performed as described above.
- a colony of F. occidentalis was established from eggs provided by D. Ullman's laboratory and maintained in a growth chamber at 26 °C and a photoperiod of 16 hours of light and 8 hours of dark. The colony was raised in plastic containers and maintained on green bean pods that were replenished about 2-3 days. Larvae were collected with soft brush at about 5-6 days after oviposition, representing a mixture of first and second instar larvae.
- plaques identified as positive in the first round of screening were removed with Pasteur pipettes (wider ends, about 0.8 cm radius) and incubated for 2 hours in 2% chloroform SM buffer (Stratagene ⁇ -ZAP kit). Resuspended phages were titered by plaque assay and 2 x 10 4 pfu from each positive clone were plated in 50 mm plates and the screening process (steps 1-6) was repeated.
- fusion proteins Overexpression of fusion proteins was performed as described by Huang and Jong, "Expression and preparation of fusion proteins from recombinant ⁇ gtl 1 phages," cDNA Library Protocols. 241-246 (Cowell and Austin (eds.) Humana Press, New Jersey (1997)) with some modifications.
- the selected recombinant phages were used to infect E. coli XL-1 blue (2 x 10 4 pfu/plate). Phages and cells were incubated for 3.5 hours at 42°C, added to 10 ml of LB medium (Sambrook et al., supra) containing 1-10 mM IPTG, and incubated for an additional 3-6 hours at 37 °C.
- Thrips polypeptides-TSWV interactions were detected with anti-TSWV Gl monoclonal antibodies as the primary antibody and anti-mouse IgG-HR peroxidase conjugate as the secondary antibody. Positive signals were detected by adding ECLTM enhanced chemiluminescent reagent (Amersham) followed by film (LabScientific) exposure for 2 min to 1 hour.
- thrips clones (pTRl 11, pTR211, pTR313, pTR411, pTR621, PTR711, and pTR821) were overexpressed in E. coli XL-1 blue and fusion proteins were purified by virtue of their ⁇ -galactosidase affinity. Binding of TSWV to a 50 kDa protein present in thrips total protein extracts was detected, as reported previously by Bandla et al., supra, as a control. TSWV binding to four different polypeptides (pTR411, pTR711, pTR821, and pTR621) selected from the thrips cDNA library was also detected. A stronger signal was observed with pTR621 which may represent higher TSWV affinity and/or higher concentration of the TR621 polypeptide in the E. coli lysate.
- Plasmid DNA derived from the 7 positive pfus (pTRl 11, pTR211, pTR313, pTR411, pTR621, pTR711, and pTR821) were in vivo excised and purified. Thrips inserts were then sequenced with T3 and T7 primers, and analyzed using the UWGCG package (Devereux et al., Nucleic Acid Res.. 12:387 (1984)), the BLAST and FASTA programs and the DNAStarTM software (DNAStar Inc.).
- ⁇ -integrins the characteristic binding motif of ⁇ - integrins (the ⁇ chain integrin domains signatures) which comprises about 20 residues [Cx(G, N, Q)x ⁇ l,3 ⁇ GxCxCx2CxC] and three additional GC-rich region motifs localized in a region of approximately 200 nucleotides (ferredoxin, a defensin and a EGF-like protein domains), detected by the MOTIFS program of the UW-Genetics Comuter Group package (Devereux et al., supra). These same domains, and only them, were also found in other ⁇ integrin sequences, such as a Drosophila ⁇ integrin.
- all seven of the positively selected TSWV-binding polypeptides have an ORF in-frame with the lacZ gene in which they were cloned, and would code for polypeptides of about 25 to 30 kDa. They also have potential glycosylation signals; and polyadenylation and stop signals in the correct positions.
- pTR411 shares homology with cytochrome C sequences (95% identity at the amino acid level); pTR911 shares homology with a defensin protein (95% identity at the amino acid level); pTRl 11 shares homology with several transcription factors, mainly the homeodomain protein (57% identity at the amino acid level); and pTR313 shares homology with the bluebottle fly Calliphora vicina arylphorin receptor (50% identity at the amino acid level).
- pTR411 shares homology with cytochrome C sequences (95% identity at the amino acid level)
- pTR911 shares homology with a defensin protein (95% identity at the amino acid level)
- pTRl 11 shares homology with several transcription factors, mainly the homeodomain protein (57% identity at the amino acid level)
- pTR313 shares homology with the bluebottle fly Calliphora vicina arylphorin receptor (50% identity at the amino acid level).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention provides a novel method for identifying virus-binding polypeptides (putative viral receptors) and the nucleotide sequences encoding them. The method uses a cDNA expression library made from the total mRNA of an animal virus vector and a freshly purified preparation of a plant-infecting virus. Also disclosed are polypeptides identified from the western flower thrips which bind to the tomato spotted wilt virus.
Description
IDENTIFICATION OF VIRUS-BINDING POLYPEPTIDES AND NUCLEOTIDE SEQUENCES
CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority from U.S. provisional patent application serial number 60/147,606, filed August 6, 1999.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
OR DEVELOPMENT Under investigation.
BACKGROUND OF THE INVENTION In animals, viruses generally enter host cells by the stepwise process of virus attachment, fusion and penetration. The attachment to the putative viral receptor, or virus-binding polypeptide, is the first event in this process. In the past and recent years, a diversity of cellular receptors have been identified for numerous animal viruses in the surface of their host cells. These receptors include, for example, the receptors for the human immunodefficiency-1 retrovirus (Dalgleish et al, "The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus," Nature, 312:763-767 (1984)); the hepatitis A herpesvirus (Kaplan et al., "Identification of a surfce glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus," EMBO J.. 15:4284-96 (1996)); the rabies rhabdovirus (Hanham et al., "Evidence from the anti-idiotypic network that the acetylcholine receptor is a rabies virus receptor," _ Virol.. 67:530-542 (1993)); and the human adenovirus type 2 (Wickham et al., "Integrins αvβ3 and 0^5 promote adenovirus internalization but not attachment," Cell, 73:309-313 (1993)). As a result of these discoveries, a better understanding of host range, tissue tropism, and virus entry mechanisms has evolved, opening the door for the development of novel therapeutic strategies for animal and human viral diseases.
Unlike animal viruses, plant viruses generally do not utilize viral receptors for entry into plant cells or for cell-to-cell movement. Plant viruses are usually introduced into their plant host cells via the feeding of invertebrate vectors or via mechanical action using a process that involves the partial destruction of the plant's cell wall and perforation of its cellular membrane. Once introduced into the cell, the virus is then able to move from cell-to-cell using the filamentous structures between the cells, known as plasmodesmata.
Some plant viruses, however, also infect and replicate in natural insect vectors just as animal viruses infect and replicate in their animal hosts. As with animal viruses, these plant viruses are thought to enter the cells of their animal vectors via the recognition of virus-binding proteins, or putative viral receptors. For example, the tomato spotted wilt virus (TSWV, Bunyaviridae), the type member of the Tospovirus genus, replicates in and is transmitted in nature by several species of thrips which have an extremely high reproductive capacity, mainly the western flower thrips, Frankliniella occidentalis Pergande.
The viral family Bunyaviridae has more than 300 members, making it one of the largest viral families. First established in 1980, the Bunyaviridae family includes five genera: Bunyavirus, Hantavirus, Nairovirus, Phlebovirus and Tospovirus, encompassing some of the most dangerous of the emergent group of pathogens. With the exception of the hantaviruses, which are transmitted by rodents excreta aerosols, all other members of the Bunyaviridae are transmitted by arthropods (mosquitos, sand flies, ticks, and thrips). Vertebrate hosts include humans, and other primates, mammals, birds, and ungulates.
The genus Tospovirus is the only known viral genus in the Bunyaviridae family that is made up of plant-infecting viruses. They have an extremely wide host range and infect hundreds of plant species, ultimately causing diseases in many economically important cereal, vegetable, ornamental and fruit crops throughout the world. Examples of important plant hosts include potato, tomato, pepper, peanut, tobacco, pea, lettuce, cotton, onion, watermelon, chrysanthemum, impatiens, begonia, dahlia and others. Diseases caused by tospoviruses are also extremely difficult to control. The rarity of genetic resistance in commercial varieties, the severity of the diseases, the large and overlapping host ranges of both the viruses and their vectors, and the development
of insecticide resistance by thrips vectors are the most important reasons for increasing economic losses caused by the tospoviruses. Devastating effects in entire fields are common throughout the world and concerns about the spread of the virus have often resulted in the increased use of chemical pesticides, thus increasing both the existence of potentially harmful chemical pollution and human health risks.
In addition to the tospoviruses, an enormous number of other plant viruses show a very specific relationship with virus vectors, mostly insects, wherein each virus or group of viruses is transmitted only by a specific vector. The specificity of each virus to its vector may be determined at the molecular level by recognition of a receptor, or other recognition or binding factors which stabilize or protect the virus in the vector organism. A number of different approaches have been used for identification and cloning of virus receptors, with the vast majority relying upon the capability of the virus or its viral attachment protein(s) to bind to host cells or to cell components. For example, putative receptors have been partially purified by affinity chromatography, and then used for the development of anti-receptor antibodies and/or microsequencing, followed by use for immuno (Baldwin et al., "Molecular cloning and expression of receptor peptides that block human cytomegalovirus/cell fusion," Biochem. Biophvs. Res. Commun.. 219:668-673 (1996)) or hyrbridization screening (Holmes et al., "Characterization and expression of the receptor glycoprotein for mouse hepatitis virus," New aspects of positive-strand RNA viruses. 253-256 (Brinton and Heinz (eds.) ASM Press, Washington D.C. 1990); Cao et al., "Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus," Science. 282:2079-81 (1998)). Alternatively, cell lines resistant to virus attachment and/or entry have been transformed with libraries derived from susceptible cell lines. Subsequently, screening is performed by either virus binding assay, virus infection, or by virus- encoded reporter gene expression (Feng et al., "HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor," Science. 272:872-877 (1996); Montgomery et al., "Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family," CeU, 87:427-436 (1996); Golovkina et al., "A novel membrane protein is a mouse mammary tumor virus receptor," J. Virol.. 72:3066-71 (1998)).
The most common approach, however, involves the identification of antibodies with the ability to block virus infection in neutralization experiments. Additional examples of virus receptor cloning strategies include the use of the yeast two-hybrid screening system (Matsumoto et al., "Hepatitis C virus core protein interacts with the cytoplasmic tail of lympho-toxin-beta receptor, " J. Virol.. 71 : 1301 - 1309 ( 1997)) and the phage display library system (Ban et al., "Isolation and characterization of a 2.3- kilobase-pair cDNA fragment encoding the binding domain of the bovine leukemia virus cell receptor," J. Virol.. 67:1050-57 (1993); Krikbaev et al., "Mutant CD4 molecules with improved binding to HIV envelope protein gpl20 selected by phage display," Virology. 234:196-202 (1997)).
All of these approaches generally require one or more of the following prerequisites: (1) a cellular virus infection or virus binding system, (2) partial or complete purification of the putative receptor, and/or (3) identification, cloning and expression of a functional viral attachment protein. Although these requisites are normally available and relatively easy to obtain in animal virus systems, they are not commonly accessible for plant viruses or are enormously difficult to obtain because of their intrinsic characteristics. Accordingly, relatively few plant viral receptors have been identified.
BRIEF SUMMARY OF THE INVENTION The present invention is summarized in that a novel method is disclosed for identifying virus-binding polypeptides, and the nucleotide sequences encoding them. Also disclosed are nucleotide sequences encoding tospovirus-binding polypeptides from the western flower thrips, Frankliniella occidentalis Pergande ("WFT"), identified using the method of the present invention.
The present invention includes a method for identifying virus-binding polypeptides comprising the steps of constructing a cDNA library from total mRNA isolated from a virus vector; inducing expression of the cDNA library to obtain fusion polypeptides; transferring the fusion polypeptides onto a membrane; exposing the membrane to at least one viral particle; and detecting those expression products which bind to the viral particle. In addition, the cDNA library member associated with the bound fusion polypeptide may be sequenced to elucidate its nucleotide sequence.
The present invention also includes nucleotide sequences encoding tospovirus- binding polypeptides identified in the western flower thrips, Frankliniella occidentalis Pergande, in accordance with the present invention.
The present invention further includes a transgenic plant expressing a foreign protein encoded by a nucleotide sequence encoding a tospovirus-binding polypeptide identified in the western flower thrips, Frankliniella occidentalis Pergande, in accordance with the present invention.
It is an object of the present invention to provide a simplified method for identifying virus-binding polypeptides in organisms. It is also an object of the present invention to provide nucleotide sequences which encode virus-binding polypeptides that may be used in strategies intended to control viral infection and transmission.
It is one advantage of the present invention that virus-binding polypeptides, and their nucleotide sequences, can be identified without requiring a cellular virus infection or binding system.
It is another advantage of the present invention that virus-binding polypeptides, and their nucleotide sequences, can be identified without requiring partial or complete purification of the putative receptor.
It is yet another advantage of the present invention that virus-binding polypeptides, and their nucleotide sequences, can be identified without requiring identification, cloning and expression of a functional viral attachment protein.
Other objects, advantages and features of the present invention will become apparent from the following specification.
BRIEF DESCRIPTION OF THE DRAWINGS AND FIGURES. Fig. 1 is a graphical illustration of Tospovirus morphology and structure, genome organization, replication and expression strategies.
Fig. 2 is an illustration of the method for cloning virus-binding polypeptides. Fig. 3 is a diagram illustrating the screening process. Fig. 4 is a table summarizing the results from a sequence analysis. Fig. 5 is a conceptual drawing representing the working hypothesis for receptor
and co-receptor recognition by TSWV.
Fig. 6 is a conceptual drawing representing the blocking of virus-receptor recognition by the expression of a virus-binding polypeptide in transgenic plants.
Figure 7 is a conceptual drawing illustrating the mechanism of virus acquisition when vectors feed on infected plants.
DETAILED DESCRIPTION OF THE INVENTION Describe here is an alternative and rapid method for the identification and cloning of virus-binding polypeptides, and the nucleotide sequences encoding such polypeptides, the polypeptides binding to plant-infecting viruses. The method uses a cDNA expression library made from the total mRNA of a virus vector organism and a freshly purified preparation of a plant-infecting virus. The method is a variation of the far- Western technique in which protein-protein interactions can be detected similarly to the traditional antigen-antibody interactions detected in Western blotting. The process does not require cellular infection, nor another viral binding system, nor the identification of the viral protein responsible for binding in the virus. The purification of a putative viral receptor from the virus vector organism is also not required. Techniques such as the one described here are not normally used in studies of plant viruses, since plant viruses do not use receptors when infecting plant cells.
In the Examples below, the invention will be described in detail in connection with the identification of TS WV-binding polypeptides from the western flower thrip, Frankliniella occidentalis Pergande. It will be understood that the principles of the invention apply as well to other types of plant-infecting viruses that use animal vectors, such as rhabdoviruses and other types of tospoviruses, such as the impatiens necrotic spot virus. Likewise, it will be understood that the principles of the present invention apply as well to other types of virus vectors, such as insects (e.g., mosquitos, sand flies, flies, and thrips), rodents, birds and other arthropods.
In general, the identification of virus-binding polypeptides in accordance with the present invention begins by constructing a cDNA expression library from the total mRNA of a virus vector animal. As used herein, a "virus vector" is defined to include those animals capable of carrying and transmitting viruses. For example, virus vectors
may include insects (e.g., mosquitos, sand flies, flies, and thrips), rodents, birds and other arthropods. In particular, virus vectors may include insects capable of carrying and transmitting bunyaviruses, nairoviruses, phleboviruses, rhabdoviruses and tospoviruses, such as the western flower thrips, Frankliniella occidentalis Pergande ("WFT"), which is known to carry and transmit the tomato spotted wilt virus ("TSWV"). The cDNA library may be constructed using any one of the many molecular vector systems commonly known in the art. For example, the lambda-based cDNA synthesis kit (Stratagene) may be used for the cDNA library construction. Lambda- based cDNA expression libraries show several advantages when compared to other methods. In vitro packaged λ phages are more efficient than plasmid DNA for E. coli transformation. Lambda libraries are also easier to amplify, plate, screen, and store more than plasmid libraries. Moreover, lambda expression libraries possess a higher size limitation for the introduced inserts when compared to other phage display libraries. Once constructed, the cDNA library may be plated and cultured to begin the screening process. In general, the screening process involves the use of a preparation of a plant-infecting virus to screen the fusion polypeptides produced by the members of the cDNA library to detect which fusion polypeptides, if any, exhibit virus-binding activity. The screening may be performed on any solid substrate suitable for protein detection, such as a nitrocellulose membrane, nylon membrane or pdf membrane. The detection system used may include any one of the many labeling systems employed in screening expression libraries. Such systems include, for example, monoclonal or polyclonal antibody systems which are selective to viral proteins.
Fusion polypeptides are obtained by inducing expression of the plated cDNA library using an inducer which promotes transcription of the cDNA insert. The inducer may be applied to the cDNA library independently or in association with the membrane to facilitate the transfer of the fusion polypeptides to the membrane.
To perform the actual screening, the fusion polypeptides are transferred onto the membrane where they are exposed to a preparation of a plant-infecting virus. The preparation will generally include a purified solution of a native virus of interest, but may also include a solution of purified viral particles (native viral proteins). When viral particles are used, the most external viral protein is likely to be the actual binding ligand
(viral glycoproteins in enveloped viruses, or capsid proteins in non-enveloped viruses), with antibodies against these proteins used for detection. By using such purified viral particles, instead of recombinant viral proteins, one can avoid potential problems with non-specific or abrogated binding caused by structural differences between the recombinant and the native viral protein, and additionally the viral protein cloning becomes an unnecessary process step.
The initial advantage of using the present method is that several complex process steps are rendered unnecessary in the cloning process of the virus-binding polypeptide. For example, the present invention does not require the induction of a cellular infection and/or a cellular binding system, or the identification, cloning and expression of a functional viral attachment protein, or the partial purification of a putative receptor.
In addition, by using the method of the present invention, several virus receptor candidates can be selected and cloned in a very short period of time, and used in subsequent experiments for determination of their biological relevance as a virus receptor. Moreover, the present method does not eliminate the selection of polypeptides which are unrelated to the virus receptor, but bind to the virus with a similar or higher affinity, which can be as useful or even more useful than a virus' specific receptor in terms of the development of novel control strategies.
The present method may also be used for deciphering other virus-host interactions, including the detection and identification of cytoplasmic host factors involved in virus replication, transcription, and/or pathogenesis when other viral proteins are used in the screening (e.g., the viral polymerase or the movement of the protein and their specific antibodies).
The identification of virus-binding polypeptides may also lead to the discovery of control strategies via the development of inhibitors of virus entry, replication, transcription, movement and transmission. For example, direct expression in transgenic plants of DNA sequences encoding viral binding polypeptides is expected to result in virus tolerant and/or resistant plans. Virus-binding polypeptides may also be used for identification of virus attachment proteins (receptor-binding) which, in turn, can be fused to specific toxins and then expressed in transgenic plants to accomplish the specific control of insect vectors.
For example, the present method has been used to identify seven DNA sequence from the western flower thrips, Frankliniella occidentalis Pergande, which encode polypeptides that specifically bind to the tomato spotted wilt virus ("TSWV"). The seven DNA sequences are partial sequences, i.e. not the entire sequence of native thirps genes, but encode sufficient portions of the binding domains of the thrips genes to bind TSWV virions. The sequences have been identified as pTRl 11 (SEQ ID NO:l), pTR211 (SEQ ID NO:2), pTR313 (SEQ ID NO:3), pTR411 (SEQ ID NO:4), pTR621 (SEQ ID NO:5), pTR711 (SEQ ID NO:6), and pTR821 (SEQ ID NO:7).
As a typical member of the Bunyaviridae family, TSWV has three single- stranded RNA segments encapsulated by a lipidic envelope of host origin. The virion contains four structural proteins including the L polymerase, the N nucleocapsid and two viral-encoded glycoproteins embedded in the envelope, Gl and G2, as all illustrated in Fig. 1.
Recent studies have reported that the viral glycoproteins may serve as viral attachment proteins for several enveloped viruses, an expected property because of the proteins external position in the virus particle. The Arginine-Glycine-Aspartate (RGD) motif has also been established as an integrin-receptor binding motif as it is typically found in glycoproteins of the extracellular matrix in both animal and plant cells, the RGD motif believed to be involved in adhesion of cells to the extracellular matrix. Recently Gavrilovskaya et al. found that β integrins are the cellular receptors for Hantaviruses, the very important human pathogens which are also members of the Bunyaviridae family. Gavrilovskaya et al., "3 integrins mediate the cellular entry of hantaviruses that cause respiratory failure," Proc. Natl. Acad. Sci. USA. 95:7074-7079 (1998). Gavrilovskaya et al. observed that hantavirus entry is RGD-independent, in agreement with the observation that Hantaviruses do not have an RGD sequence in their glycoprotein ORF. Nonetheless, an RGD motif is present in the 5' end of G2 in two tospoviruses, TSWV and Impatiens necrotic spot virus (INSV) and its role as a receptor- binding motif together with the role of β integrins as tospoviruses receptors are questions still not addressed. As mentioned above, Gavrilovskaya demonstrated that β3 integrins specifically mediate the entry of two different hantaviruses in their respective host cells and, thus,
proposed β-integrins as the hantavirus receptor. Our sequence analysis indicates that we have cloned at least parts of one or several thrips integrins or integrin-like proteins using the virus-binding selection process of the present invention and a purified TSWV prepartion. Accordingly, this indicates that Tospoviruses may also use β integrins as cellular receptors, which is plausible in evolutionary terms. This hypothesis is substantiated by other data and observations. The Arg-Gly-Asp (RGD) motif has been extensively characterized as the β integrin binding domain and it is present in the G2 sequence of TSWV and INSV. In addition it has been previously demonstrated that TSWV is acquired just by larval stages and that the TSWV receptor is localized in larval midguts.
Our results also show that TSWV binds to some transcriptional activator-like thrips polypeptides which, if confirmed in vivo, might represent TSWV co-receptors and a novel mechanism for virus entry. Figure 5 illustrates a model for the proposed interactions between these factors. Several potential novel virus control strategies based on the seven sequences presented here, as well on virus-binding sequences discovered in accordance with the method of the present invention, are plausible. One approach is based on the use of transgenic plants engineered to express the virus-binding polypeptides. These plants are expected to inhibit transmission by interfering with virus particles assembly (virus assembly is necessary for virus acquisition by thrips). In particular, the polypeptides will bind to the viral glycoproteins and block its interaction with virus RNAs. Alternatively, or concomitantly, these plants are expected to inhibit transmission by interfering with virus-receptor recognition. More specifically, virus-binding polypeptides will saturate receptor binding sites on the virus surface and prevent virus- receptor interaction in thrips vectors. This strategy is illustrated in Fig. 6.
The inhibition of virus transmission caused by virus-binding polypeptides is expected to be effective against all or most tospoviruses because TSWV glycoproteins share about 80% identity with others in the genus. This provides a significant advantage over transgenic plants expressing the N gene, as plants transfected with the N gene are resistant only against the isolate from which the N gene was extracted. Additionally non-binding mutant viruses that will eventually arise would not be transmitted.
Another envisioned approach is based on the use of vector specific biological pesticides. Virus-binding polypeptides exclusively found in vector species will be used for selection of specific ligands (TSWV glycoproteins). These specific ligands will be used in the construction of Bt toxin-fusion proteins that will be expressed in transgenic plants or sprayed on plants in the field. Such biopesticides will target tospovirus vectors while avoiding non-vector species.
Another potential approach is based on the identification of chemical compounds and peptides that block TSWV-thrips interaction. Identified virus-binding polypeptides will be used for screening chemical compounds and small peptide libraries. Compounds and/or peptides that disrupt virus binding could be expressed in transgenic plants to inhibit viral binding directly or could be used to design virus-vector interaction blocking agents.
Yet another potential strategy could be based on the use of transgenic plants expressing the viral attachment protein (VAP) or a specific VAP domain. The cloning and identification of the TSWV thrips receptor and TSWV-binding thrips polypeptides will lead to the VAP identification, when expressed in a transgenic plant the VAP will flood the thrips receptor and block transmission.
The method described here can be also be adapted to the cloning of polypeptides that bind any viral proteins (L and/or N for example). Purified recombinant L and N proteins can be used in substitution to the whole virus particle in the overlay step and, instead of TSWV glycoproteins-bound polypeptides, polymerase- or capsid-bound polypeptides can be identified and cloned. Subsequently transgenic plants expressing these polypeptides can be obtained and are expected to be resistant to virus infection via interference with virus replication.
EXAMPLES
Detection of specific TSWV-bound thrips factors using far- Western assays.
Experiments were performed to confirm the existence of specific virus-binding factors in thrips vectors already been reported (Bandla et al., "Interaction of tomato spotted wilt tospovirus (TSWV) glycoproteins with a thrips midgut protein, a potential
cellular receptor for TSWV, Phytopathology. 88:98-104 (1998)). As expected, specific TSWV-bound thrips factors were detected only in F. occidentalis using far- Western and Western blotting assays performed as described.
Monoclonal anti-Gl/G2 antibodies (Bandla and Sherwood, "Production of monoclonal antibodies to the glycoproteins of tomato spotted wilt virus using antigens eluted from ChromaPhor stained gels," Phytopathology. 85:1205 (1995)) were coupled to Sepharose C1-4B beads (Sigma) by addition of cyanogen-bromide as described by Ausubel et al., Short Protocols in Molecular Biology. (John Wiley and Sons, Inc., New York, 1995), producing an antibody-Sepharose complex (Ab-Seph). TWWV was purified as described by Gonsalves and Trujillo, "Tomato spotted wilt virus in papaya and detection of the virus by ELISA," Plant Disease. 70:501-506 (1986), resuspended in 0.01 M NaSO3 to 2 μg/μl total protein and immediately incubated for 2 hours at 4°C with Ab-Seph (1 vol virus: lOvol Ab-Seph), resulting in the Ab-Seph-TSWV conjugate. Thrips and mosquito (Anopheles gambiae Giles) extracts were homogenized in SDS lysis buffer (0.5% SDS, 0.05 M Tris-HCl, pH 8.0, ImM DTT, 2mM leupeptin and pepstatin, 20mM iodoacetamide, 1 mM PMSF) at 4 μg/μl total protein, boiled 5 minutes, added to 1 vol of RIP A correction buffer (1.25% NP-40, 1.25% Na- deoxycholate, 0.0125M NaPO4, pH 7.2, 2mM EDTA, 0.2 mM Na-vanadate, 50 mM Na- fluoride, 100 U/ml aprotinin, 2mM leupeptin and pepstatin, 20 mM iodoacetamide, ImM PMSF) and incubated 1 to 4 hours at 4°C.
The insect extracts were then incubated with the Ab-Seph/TSWV conjugate (1:1 vol., empirically determined) for an additional 3 hours at 4°C. After this further incubation period, the mixture was centrifuged for 1 min at 10,000 x g in washing buffer (1% Triton X-100, 1% bovine hemoglobin, pH 8.0, 0.14 NaCl, 0.025% NaN3, 1% sodium dowxycholate, 0.1% SDS, 1 mM DTT), the surpematant was discarded and the pellet was resuspended in washing buffer.
The washing step was repeated three times and the final pellet was resuspended in 10 vols of Laemmli buffer (60mM Tris pH 6.8, 0.1% bromophenol blue, 2.5% BME, 5% SDS), boiled 5 min, and submitted to 7.5% SDS-PAGE. To detect thrips proteins immunoprecipitated by the Ab-Seph-TSWV conjugate, a far- Western assay was performed as described by Bandla et al., supra, with some
modifications as will be described. After overnight electroblotting (1 V/cm) and incubation in a blocking solution [5% non-fat dry milk, 0.5% Tween-20, and TBE buffer] for 2 hours, nitrocellulose membranes were incubated with purified TSWV diluted in fresh blocking solution at 10 μg/ml of total protein overnight at 4°C. For visualization, monoclonal anti-Gl antibody (1 : 100 in blocking solution) was used as primary antibody and anti-mouse IgG-horseradish peroxidase conjugate (Sigma) as the secondary antibody (1 :25,000). The ECL™ enhancer chemiluminescent reagent (Amersham) was used as substrate for detection followed by exposure of the blot to X- ray film (Kodak and LabScientific). As positive and negative controls, thrips and mosquito whole extracts (120 μg of total protein) were prepared in Laemmli buffer as described above. The thrips extracts were prepared suing larval stages since the previously detected 50 kDa candidate receptor protein is more abundant in larval than in adult extracts.
Membranes were sequentially incubated in stripping buffer (2% SDS, 100 mM BME, 62 mM Tris, pH 6.8) 50 °C for 30 minutes to remove TSWV virions and antibodies, according to the manufacturers instructions (Amersham), and re-probed only with anti-Gl and secondary antibodies, without previous incubation with purified TSWV. Four additional immunoprecipitation buffers containing nonionic detergents as Triton-XlOO and Nonidet-P40 (described in Ausebel et al, supra) were tested (data not shown), as well as buffering conditions.
Next, anti-idiotypic antibodies (anti-Ids) raised against anti-Gl /G2 monoclonal antibodies (Bandla et al., supra) were coupled to Sepharose beads as described before. The resulting anti-Ids-Seph complex was incubated with the insect extracts (1:1 vol) for 3 hours at 4°C, washed three times, resuspended in Laemmli buffer and boiled for 5 minutes.
The Western blotting assay was conducted as described above but without any virus overlay, while anti-idiotypic antibodies raised against anti-viral glycoproteins antibodies obtained previously were used as the primary antibodies. Mosquitoes (Aedes triseriatus, A. albopictus and Anopheles gambiae) were used as negative controls. To decrease the background cross-reaction observed by Blanda et al., supra, when using the anti-Ids, the antibodies were cross-absorbed (an anti-IdGl+anti-IdG2
mixture) by incubation with whole mouse serum (Sigma) at 4 °C for 3 hours, and collecting the supernatent after 30 minutes of centrifugation at 14,000 x g in a microcentrifuge. Chemiluminescence relative to background of the detected 50 kDA proteins was measured with Lumi-Imager™ (Boehringer Mannheim) in Boehringer light units (BLU)(representing the chemiluminescent light released by the peroxidase-luminol reaction.)
The far- Western assay detected a 50 kDa thrips factor (protein) in the thrips extracts as previously reported by Bandla et al., supra, possibly representing the TSWV receptor or a receptor component. A second factor at about 65 kDa was also detected, although less evident, possibly representing a second receptor or receptor component. Both thrips proteins were also detected in the Western blotting assay when anti-idiotypic antibodies (anti-Ids) were utilized as the primary antibody. Such anti-Ids are considered to mimic the original ligand structure and are frequently used for receptor recognition in several different systems (Gaulton & Greene, 1986).
Construction of cDNA Library
Total RNA and mRNA purification and analysis
Total RNA was extracted from 100 mg of 2nd instar F. occidentalis larvae and adults and Drosophila melanogaster using TRI™ reagent (Sigma, St. Louis, MO) and aurin tricarboxylate (as RNase inhibitor) as described by Dinesh-Kumar and Miller, "Control of start codon choice on a plant viral RNA encoding overlapping genes," Plant Cell. 5:679-692 (1993). Poly(A)+RNA (mRNA) was purified by affinity chromatography using biotin-oligo(dT)-streptavidin beads (PolyATract™, Promega, Madison, WI) in three rounds of purification. Northern hybridization analysis of total and mRNA samples was performed after formaldehyde- 1% agarose gel electrophoresis using an actin universal DNA probe (pActin-1 clone, provided by the S. Carroll's laboratory, Dept. Genetics, UW-Madison) labeled with [α-32P]-dATP to monitor the synthesis reaction. Rnase H, DNA polymerase I, and dNTPs were then added to the first-strand synthesis reaciton product (a DNA/mRNA hybrid) to obtain the second- strand cDNA by 'nick translation'. 100 μg of total RNA and 5 μg of poly(A)+RNA were obtained from the 100 mg
of F. occidentalis larval tissue. Final poly(A)+RNA samples had an OD260/ 8o = 1.8. Ribosomal RNA bands were visualized on a 1% denaturing agarose gel by ethidium bromide staining. Analysis of the results showed the 18S rRNA a and b fragments at the 1.8 kb position, as expected. In addition, a Drosophila melanogaster actin probe hybridized to an 800 bp RNA species, as expected, before and after mRNA isolation. These results indicate that the RNA samples utilized were of appropriate quality.
cDNA first- and second-strand synthesis
The λ-ZAP cDNA synthesis kit (Stratagene, San Diego, CA) was used according to the manufacturer's instructions with some modifications. Poly(A)+RNA was added to oligo(dT) linker-primer (5* GAGAGAGAGAGAGAGAGAGAACTAGTCTCGAGT TTTTTTTTTTTTTTTTT 3'), which contains an.λ7jøl site (underlined) for sense- oriented insertion in the UniZAP XR λ vector, with respect to the lacL promoter, a GAGA sequence to protect the restriction site, and a 18-base poly(dT) sequence that binds to the 3' poly(A) region fo the mRNA templates, MMLV reverse transcriptase, 5- methyl dCTP (to protect the cDNA from subsequent digestion reaction), and dNTPs to obtains the first-strand cDNA using [α"32P]-dATP to monitor the reaction. Rnase H, DNA polyerase I ("nick-translation"), and dNTPs were then added to the first-strand synthesis reaction product (a cDNA/mRNA hybrid) to obtain the second-strand cDNA by 'nick translation'. The results visualized on a gel showed a smear of cDNA products extending from 0.1 kb to about 12 kb in a 1% alkaline agarose gel, indicating successful synthesis of a wide range of cDNA. RNA extracted with aurin tricarboxylate resulted in a wider range of cDNA when compared to RNA extracted with TRI™ reagent. Also visualized was a range of cDNA fragments that were size-fractionated (0.5-10kb) and used in the ligation reaction to the λ-ZAP XP vector (Stratagene). Primary library titer was determined by plaque assay as 2 x 105 pfu and 6 x 109 pfu/ml after amplification.
Obtaining recombinant λ phage
Total F. occidentalis cDNA samples were blunted at the ends with Pfu DNA polymerase. EcoRl adapters (a 9- and 13-mer oligonucleotides, complementary to each
other with an EcoRI cohesive end) were added by T4 DNA ligase and the reaction product was digested with_Λ72oI. Since the EcoRX adapters were ligated to both ends and the cDNA was not methylated at the linker-primer region, the XhόX. digestion reaction released XhoX. and EcoRX cohesive ends. To avoid cloning of sequences mostly derived from tRNA and small rRNA, size fractionation was carried out by electrophoretic separation of cDNA products on a 1% low melting agarose gel. After 2 hours at 20mA, cDNA fragments ranging from 0.5 to 10 kb were recovered by silica-gel columns (QIAquick™, Qiagen, St. Clarita, CA). After gel recovery, cDNA inserts were ligated in the Uni-ZAP XR λ vector containing XhoX and EcoRX cohesive ends for directional cloning into the pBluescript plasmid sequence, under the control of the lacZ promoter (Stratagene), using T4 DNA ligase according to the manufacturer's instructions. The Gigapack II extract (Stratagene) was used for in vitro packaging of the recombinant phages (Kretz et al., " Gigapack® III high efficiency lambda packaging extract with single-tube convenience," Strategies Mol. Biol., 7:44-45 (1991)), resulting in infectious recombinant λ phase particles.
Titration and amplification
The primary library was produced by infecting E. coli XL 1 -blue (Bullock et al., "XL 1 -blue: A high efficient plasmid transforming recA Escherichia coli strain with β- galactosidase selection," BioTechniques. 5:376-379 (1987)) with the above recombinant phages. Titer was determined by a plaque assay to reveal a titer of 2 x 105 pfu.
Because primary libraries are generally unstable and normally insufficient for repeated rounds of screening, amplification was performed by re-infection in E. coli XL 1 -blue following the manufacturer instructions (Stratagene' s λ-ZAP cDNA synthesis kit). A titer of 6 x 109 pfu/ml was obtained. One ml of the amplified library was stored at 4°C for immediate use in the subsequent screening steps and the remaining 20 ml was stored at - 80 °C with 7% DMSO.
Average size of the thrips inserts
Thirty-one different recombinant plasmid vectors (in a pBluescript background)
were isolated at random from the thrips cDNA library and excised in vivo using co- infection with fl helper phage (Short and Sorge, "In vivo excision properties of bacteriophage λZAP expression vectors," Meth. EnzvmoL. 216:485-508 (1992)), according to the manufacturer's instructions (Stratagene), and purified via alkalyne lysis (Sambrook et al., Molecular Cloning: A Laboratory Manuel. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989)). After in vivo excision, the derived plasmids were digested with XhoX /EcoRX restriction enzymes, followed by visualization on 1% agarose gel with ethidium bromide using UV transilluminator (NucleoTech NucleoVision), to determine the average size of the thrips cDNA inserts. The thirty-one cDNA fragments were visible on 1% agarose gel, with the XhoXIEcoRX inserts present in a 0.5 to 1.7 kb range. Figure 2 shows a diagram illustrating the process of the library construction.
Virus maintenance and insect colony
The TSWV Hawaiian strain was maintained by thrips inoculation in Datura stramonium (provided by D. Ullman's laboratory, Dept. Entomology, UC-Davis). Virus purification was performed as described above. A colony of F. occidentalis was established from eggs provided by D. Ullman's laboratory and maintained in a growth chamber at 26 °C and a photoperiod of 16 hours of light and 8 hours of dark. The colony was raised in plastic containers and maintained on green bean pods that were replenished about 2-3 days. Larvae were collected with soft brush at about 5-6 days after oviposition, representing a mixture of first and second instar larvae.
Screening for TSWV-Binding Polypeptides
Screening for TSWV-binding polypeptides was performed in three rounds as described below: First Screening Round:
1) 5 x 104 plaque forming units (pfu) were plated in 150 mm plates and incubated for 3.5 hours at 42°C. Plates were then overlaid with IPTG-impregnated nitrocellulose membranes and incubated at 37°C for 8 hours. Ten (10) plates were used since 5 x 105 was the estimated number of clones to be screened in order to have a 99%
probability of finding one gene derived from a low-abundant mRNA (Sibson and Starkey, "Increasing the average of abundance of low-abundance cDNAs by ordered subdivision of cDNA populations," cDNA Library Protocols. 13-32 (Cowell and Austin (eds.) Humana Press, New Jersey (1997)). 2) Nitrocellulose membranes were removed and incubated with a 5% dry fat milk, 0.05% Tween-20 Tris-buffered saline solution (TTBS, Sambrook et al., supra) for 30 min (blocking); plates were stored at 4°C until results were available.
3) Membranes were then incubated at 4 °C overnight with freshly purified TSWV diluted in the 5% milk TTBS solution (final concentration of TSWV = 10 μg total protein/ml of TTBS, spectophotometrically determined).
4) Membranes were washed three times at 5 minutes each in Tris-buffered saline solution (TBS, Sambrook et al., supra) and further incubated for 3 hours at room temperature with anti-Gl monoclonal antibody (MAb).
5) Membranes were washed again and incubated with anti-mouse IgG-HR peroxidase conjugate (Sigma, 1 :25 000 dilution) or anti-mouse IgG-alkaline phosphatase conjugate (Sigma 1 :25 000). Positive signals were detected by adding ECL™ enhanced chemiluminescent reagent as described by the manufacturer (Amersham, Piscataway, NJ) followed by film exposure (LabScientific, Livingston, NJ) or by adding BCIP-NBT alkaline phosphatase substrate (Sigma). Controls:
6) Anύ-Manduca sexta whole hemo-lymph polyclonal antibody (provided by the W. Goodman's laboratory, Dept. Entomology, UW-Madison) was used as a positive control at a dilution of 1 : 10 000. Negative controls included: (a) direct usage of anti-Gl Mab (at 1:100 dilution), without previous incubation with TSWV; and (b) screening of wild type λ-infected plates and TSWV and anti-Gl MAb. All controls were treated as described below for detection. Second Screening Round:
7) The plaques identified as positive in the first round of screening were removed with Pasteur pipettes (wider ends, about 0.8 cm radius) and incubated for 2 hours in 2% chloroform SM buffer (Stratagene λ-ZAP kit). Resuspended phages were titered by plaque assay and 2 x 104 pfu from each positive clone were plated in 50 mm
plates and the screening process (steps 1-6) was repeated. Third Screening Round:
8) After the 2nd round, at least 3 positive plaques/plate were isolated, resuspended in SM buffer, titered, and plated again in 50 mm plates. A third round of screening was performed as described above (steps 1-6) in order to insure that a homogenous population of positive clones had been selected and isolated. Selected recombinant plasmid vectors were then excised in vivo and transformed in E. coli DH5α.
In the first round 10 positive signals corresponding to TSWV-bound pfu were identified from a total of 5 x 105 pfu plated. In the second and third rounds 7 out of 10 selected pfu were confirmed as positives. No signals were detected on wt λ-infected plates (negative control) used in the first and third rounds when probed with anti-Gl monoclonal antibody without previous incubation of membranes with purified TSWV (data not shown). Selected pfus were purified and submitted to Eco AIXhόX digestion to confirm homogeneity of the selected phage population. Digestion analysis showed that the positively selected recombinant phages isolated from the same plate after three rounds of screening had the same insert size (data not shown). Meanwhile, randomly selected recombinant phages isolated from negatively selected plates showed inserts of various sizes (data not shown). Overall, this indicated that three rounds of screening was sufficient for isolation of the selected phages.
Overexpression of fusion proteins and far- Western assays
Overexpression of fusion proteins was performed as described by Huang and Jong, "Expression and preparation of fusion proteins from recombinant λgtl 1 phages," cDNA Library Protocols. 241-246 (Cowell and Austin (eds.) Humana Press, New Jersey (1997)) with some modifications. The selected recombinant phages were used to infect E. coli XL-1 blue (2 x 104 pfu/plate). Phages and cells were incubated for 3.5 hours at 42°C, added to 10 ml of LB medium (Sambrook et al., supra) containing 1-10 mM IPTG, and incubated for an additional 3-6 hours at 37 °C. Bacterial lysates were recovered and stored at - 80° C overnight. Next, three volumes of saturated ammonium
sulfate were added and total protein was collected by 30 min of centrifugation at 14,000 x g in a refrigerated microcentrifuge (Eppendorff). The supernatant was discarded and pellets recovered in Tris-HCl buffer, pH 7.5. β-galactisidase fusion proteins were purified via affinity chromatography using APTG-agarose (Boehringer Mannheim, Indianapolis, IN) and detected via Western blotting with anti-β-galactosidase monoclonal antibody (Boehringer Mannheim). Fusion protein concentrations' were spectophotometrically determined and adjusted to 1 μg/μl-
Far- Western assays were also carried out as described above. (Bandla et al., supra; Medeiros et al., "Immunoprecipitation of a 50 kDa protein; a candidate receptor component for tomato spotted wilt tospovirus (Bunyaviridae) in its main vector, Frankliniella occidentalis, Virus Res.. 67:109-118 (2000)). Briefly, samples were submitted to 7% SDS-PAGE, transferred to nitrocellulose membranes, and probed with purified TSWV (10 μg total protein/ml of buffer). Thrips polypeptides-TSWV interactions were detected with anti-TSWV Gl monoclonal antibodies as the primary antibody and anti-mouse IgG-HR peroxidase conjugate as the secondary antibody. Positive signals were detected by adding ECL™ enhanced chemiluminescent reagent (Amersham) followed by film (LabScientific) exposure for 2 min to 1 hour.
Positively selected thrips clones (pTRl 11, pTR211, pTR313, pTR411, pTR621, PTR711, and pTR821) were overexpressed in E. coli XL-1 blue and fusion proteins were purified by virtue of their β-galactosidase affinity. Binding of TSWV to a 50 kDa protein present in thrips total protein extracts was detected, as reported previously by Bandla et al., supra, as a control. TSWV binding to four different polypeptides (pTR411, pTR711, pTR821, and pTR621) selected from the thrips cDNA library was also detected. A stronger signal was observed with pTR621 which may represent higher TSWV affinity and/or higher concentration of the TR621 polypeptide in the E. coli lysate.
Other selected clones (pTRl 11 , pTR211 , and pTR313) also resulted in positive signals in additional far- Western assays (data not shown). No TSWV-binding was detected when Aedes triseriatus (a bunyavirus vector) total protein extract or empty pBluescript plasmid vector (pBS) were used. Overall, these results confirmed the
specific TSWV-binding capability of the selected thrips polypeptids.
Sequence Analysis
Plasmid DNA derived from the 7 positive pfus (pTRl 11, pTR211, pTR313, pTR411, pTR621, pTR711, and pTR821) were in vivo excised and purified. Thrips inserts were then sequenced with T3 and T7 primers, and analyzed using the UWGCG package (Devereux et al., Nucleic Acid Res.. 12:387 (1984)), the BLAST and FASTA programs and the DNAStar™ software (DNAStar Inc.).
As shown in the table of Fig. 4, sequence analysis revealed that all seven of the positively selected TSWV-binding polypeptides share the four conserved motifs commonly found in β-integrins. These motifs are the characteristic binding motif of β- integrins (the β chain integrin domains signatures) which comprises about 20 residues [Cx(G, N, Q)x{l,3} GxCxCx2CxC] and three additional GC-rich region motifs localized in a region of approximately 200 nucleotides (ferredoxin, a defensin and a EGF-like protein domains), detected by the MOTIFS program of the UW-Genetics Comuter Group package (Devereux et al., supra). These same domains, and only them, were also found in other β integrin sequences, such as a Drosophila β integrin.
In addition, all seven of the positively selected TSWV-binding polypeptides have an ORF in-frame with the lacZ gene in which they were cloned, and would code for polypeptides of about 25 to 30 kDa. They also have potential glycosylation signals; and polyadenylation and stop signals in the correct positions.
Three out of the seven selected clones (pTR621, pTR711 and pTR821) share 90 to 97% homology at the nucleotide level with exactly the same 3' end, although they came from different original plates, which indicates that they originated from the same gene. The prevalence of this gene probably indicates a high abundance in the WFT cDNA library as has been observed in cDNA libraries from D. melanogaster, and/or strong affinity for virus binding. Clone pTR211 showed about 20% homology to clones pTR621, pTR711, and pTR821, while the remaining clones (pTRl 11, pTR411 and pTR313) shared no homology amongst themselves or with the four clones mentioned above. All clones share some homology with proteins detected in the database. BLAST
and FASTA searches revealed that pTR621, pTR711, and pTR821 share homology (70% identity at the amino acid level) with cuticle proteins previously cloned from Anopheles spp. and other insects; pTR411 shares homology with cytochrome C sequences (95% identity at the amino acid level); pTR911 shares homology with a defensin protein (95% identity at the amino acid level); pTRl 11 shares homology with several transcription factors, mainly the homeodomain protein (57% identity at the amino acid level); and pTR313 shares homology with the bluebottle fly Calliphora vicina arylphorin receptor (50% identity at the amino acid level). However, none of the selected clones presented an entire open reading frame, therefore the significance of these similarities cannot yet be addressed.
Claims
CLAIMS We claim:
1. A method for identifying nucleotide sequences encoding virus-binding polypeptides which bind to a plant-infecting virus comprising the steps of constructing a cDNA library from total mRNA isolated from an animal virus vector; inducing expression of the cDNA library to obtain fusion polypeptides; transferring the fusion polypeptides onto a membrane; exposing the membrane to a preparation of a plant-infecting virus; detecting those fusion polypeptides which bind to the virus; and sequencing the cDNA library member associated with the fusion polypeptide.
2. The method of claim 1 wherein the virus vector is an insect.
3. The method of claim 2 wherein the virus vector belongs to the insect order Thysanoptera.
4. The method of claim 3 wherein the virus vector is Frankliniella occidentalis
Pergande.
5. The method of claim 1 wherein the membrane is selected from the group consisting of a nitrocellulose membrane, a nylon membrane and a pdf membrane.
6. The method of claim 1 wherein the preparation comprises of a purified solution of a native virus.
7. The method of claim 6 wherein the native virus is selected from the group consisting of rhabdoviruses and tospoviruses.
8. The method of claim 7 wherein the native virus is a tospovirus.
9. The method of claim 8 wherein the native virus is selected from the group consisting of a tomato spotted wilt virus and an impatiens necrotic spot virus.
10. The method of claim 1 wherein the preparation comprises at least one viral particle.
11. The method of claim 10 wherein the viral particle is from a virus selected from the group consisting of rhabdoviruses and tospoviruses.
12. The method of claim 11 wherein the viral particle is from a tospovirus.
13. The method of claim 12 wherein the viral particle is from a virus selected from the group consisting of a tomato spotted wilt virus and an impatiens necrotic spot virus.
14. A method for identifying virus-binding polypeptides which bind to a plant virus comprising the steps of: constructing a cDNA library from total mRNA isolated from an animal virus vector; inducing expression of the cDNA library to obtain fusion polypeptides; transferring the fusion polypeptides onto a membrane; exposing the membrane to a preparation of a plant-infecting virus; and detecting those fusion polypeptides which bind to the virus.
15. The method of claim 14 wherein the virus vector is an insect.
16. The method of claim 15 wherein the virus vector belongs to the insect order
Thysanoptera.
X 1. The method of claim 16 wherein the virus vector is Frankliniella occidentalis Pergande.
18. The method of claim 14 wherein the membrane is selected from the group consisting of a nitrocellulose membrane, a nylon membrane and a pdf membrane.
19. The method of claim 14 wherein the preparation comprises a purified solution of a native virus.
20. The method of claim 19 wherein the native virus is selected from the group consisting of rhabdoviruses and tospoviruses.
21. The method of claim 20 wherein the native virus is a tospovirus.
22. The method of claim 21 wherein the native virus is selected from the group consisting of a tomato spotted wilt virus and an impatiens necrotic spot virus.
23. The method of claim 14 wherein the preparation comprises of at least one viral particle.
24. The method of claim 23 wherein the viral particle is from a virus selected from the group consisting of rhabdoviruses and tospoviruses.
25. The method of claim 24 wherein the viral particle is from a tospovirus.
26. The method of claim 25 wherein the viral particle is from a virus selected from the group consisting of a tomato spotted wilt virus and an impatiens necrotic spot virus.
27. An isolated nucleotide sequence comprising DNA selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, and SEQ ID NO. 7.
28. A transgenic plant expressing a foreign protein, the foreign protein comprising a virus-binding polypeptide as is encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, and SEQ ID NO. 7.
29. A seed of the transgenic plant of claim 28.
30. A plant grown from the seed of claim 29.
31. A polypeptide encoded by the nucleotide sequence of claim 28.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14760699P | 1999-08-06 | 1999-08-06 | |
| US147606P | 1999-08-06 | ||
| PCT/US2000/021614 WO2001011090A2 (en) | 1999-08-06 | 2000-08-07 | Identification of virus-binding polypeptides and nucleotide sequences |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1242634A2 true EP1242634A2 (en) | 2002-09-25 |
Family
ID=22522214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP00952633A Withdrawn EP1242634A2 (en) | 1999-08-06 | 2000-08-07 | Identification of virus-binding polypeptides and nucleotide sequences |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1242634A2 (en) |
| AU (1) | AU6529500A (en) |
| CA (1) | CA2382646A1 (en) |
| IL (1) | IL147574A0 (en) |
| MX (1) | MXPA02000917A (en) |
| NZ (1) | NZ516487A (en) |
| WO (1) | WO2001011090A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106970080A (en) * | 2017-05-22 | 2017-07-21 | 贵州省亚热带作物研究所 | A kind of fast and convenient mango thrips monitoring method |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5877012A (en) * | 1993-03-25 | 1999-03-02 | Novartis Finance Corporation | Class of proteins for the control of plant pests |
-
2000
- 2000-08-07 CA CA002382646A patent/CA2382646A1/en not_active Abandoned
- 2000-08-07 MX MXPA02000917A patent/MXPA02000917A/en not_active Application Discontinuation
- 2000-08-07 AU AU65295/00A patent/AU6529500A/en not_active Abandoned
- 2000-08-07 WO PCT/US2000/021614 patent/WO2001011090A2/en not_active Ceased
- 2000-08-07 EP EP00952633A patent/EP1242634A2/en not_active Withdrawn
- 2000-08-07 NZ NZ516487A patent/NZ516487A/en unknown
- 2000-08-07 IL IL14757400A patent/IL147574A0/en unknown
Non-Patent Citations (1)
| Title |
|---|
| See references of WO0111090A3 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2382646A1 (en) | 2001-02-15 |
| WO2001011090A9 (en) | 2002-11-07 |
| WO2001011090A3 (en) | 2002-07-18 |
| AU6529500A (en) | 2001-03-05 |
| IL147574A0 (en) | 2002-08-14 |
| WO2001011090A2 (en) | 2001-02-15 |
| MXPA02000917A (en) | 2003-03-27 |
| NZ516487A (en) | 2004-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ghosh et al. | Transmission of a new polerovirus infecting pepper by the whitefly Bemisia tabaci | |
| Yadani et al. | The carboxy-terminal acidic domain of Rift Valley Fever virus NSs protein is essential for the formation of filamentous structures but not for the nuclear localization of the protein | |
| Medeiros et al. | The plant virus Tomato Spotted Wilt Tospovirus activates the immune system of its main insect vector, Frankliniella occidentalis | |
| Taning et al. | Engineered flock house virus for targeted gene suppression through RNAi in fruit flies (Drosophila melanogaster) in vitro and in vivo | |
| Rowley et al. | Genetic variation and virulence of nucleopolyhedroviruses isolated worldwide from the heliothine pests Helicoverpa armigera, Helicoverpa zea, and Heliothis virescens | |
| Guo et al. | Roles of cellular NSF protein in entry and nuclear egress of budded virions of Autographa californica multiple nucleopolyhedrovirus | |
| Dai et al. | Autographa californica multiple nucleopolyhedrovirus exon0 (orf141), which encodes a RING finger protein, is required for efficient production of budded virus | |
| Tatineni et al. | High Plains wheat mosaic virus: An enigmatic disease of wheat and corn causing the High Plains disease | |
| Dong et al. | Bombyx mori nucleopolyhedrovirus ORF79 is a per os infectivity factor associated with the PIF complex | |
| Ohkawa et al. | Nuclear F-actin is required for AcMNPV nucleocapsid morphogenesis | |
| Tatineni et al. | Differential synergistic interactions among four different wheat-infecting viruses | |
| Wetzel et al. | The Beta vulgaris‐derived resistance gene Rz2 confers broad‐spectrum resistance against soilborne sugar beet‐infecting viruses from different families by recognizing triple gene block protein 1 | |
| Haas-Stapleton et al. | Spodoptera frugiperda resistance to oral infection by Autographa californica multiple nucleopolyhedrovirus linked to aberrant occlusion-derived virus binding in the midgut | |
| Ghosh et al. | A C2H2 zinc finger transcription factor of the whitefly Bemisia tabaci interacts with the capsid proteins of begomoviruses and inhibits virus retention | |
| Bao et al. | Direct interactions between bidensovirus B m DNV‐Z proteins and midgut proteins from the virus target B ombyx mori | |
| Britt-Ugartemendia et al. | RNA-sequencing-based virome discovery in Florida citrus pests | |
| Kang et al. | Interaction of Bombyx mori nucleopolyhedrovirus BRO-A and host cell protein laminin | |
| Tatineni et al. | 6K1, NIa-VPg, NIa-pro, and CP of wheat streak mosaic virus are collective determinants of wheat streak mosaic disease in wheat | |
| WO2001011090A2 (en) | Identification of virus-binding polypeptides and nucleotide sequences | |
| Gilmer | Molecular biology and replication of beet necrotic yellow vein virus | |
| WO2013032999A2 (en) | Polydnavirus delivery constructs | |
| Dorrington | Advances in Tetravirus research: new insight into the infectious virus lifecycle and an expanding host range | |
| Goszczynski | Divergent molecular variants of Grapevine virus B (GVB) from corky bark (CB)-affected and CB-negative LN33 hybrid grapevines | |
| Medeiros et al. | Simplified, rapid method for cloning of virus-binding polypeptides (putative receptors) via the far-Western screening of a cDNA expression library using purified virus particles | |
| Alaoui-Ismaili et al. | Insect virus proteins (FALPE and p10) self-associate to form filaments in infected cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20020222 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
| 17Q | First examination report despatched |
Effective date: 20031008 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20060301 |